Relypsa Inc. (RLYP) Stock Rating Lowered by Vetr Inc.
Vetr cut shares of Relypsa Inc. (NASDAQ:RLYP) from a buy rating to a hold rating in a research report sent to investors on Monday morning. The firm currently has $31.16 target price on the stock.
Several other research analysts have also recently weighed in on the company. Stifel Nicolaus reiterated a buy rating and set a $36.00 price target on shares of Relypsa in a research report on Friday, July 15th. Wedbush reiterated a buy rating and set a $51.00 price target on shares of Relypsa in a research report on Friday, June 10th. BTIG Research reiterated a buy rating and set a $35.00 price target on shares of Relypsa in a research report on Wednesday, June 29th. Cantor Fitzgerald set a $41.00 price target on Relypsa and gave the company a buy rating in a research report on Thursday, July 21st. Finally, Morgan Stanley reiterated an underweight rating and set a $9.00 price target on shares of Relypsa in a research report on Tuesday, July 12th. Twelve equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $35.87.
Relypsa (NASDAQ:RLYP) opened at 31.99 on Monday. Relypsa has a 52-week low of $10.26 and a 52-week high of $32.12. The stock’s 50 day moving average price is $30.31 and its 200-day moving average price is $20.28.
Relypsa (NASDAQ:RLYP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.87) earnings per share for the quarter, missing the consensus estimate of ($1.56) by $0.31. The company earned $5.22 million during the quarter, compared to the consensus estimate of $5.45 million. On average, analysts expect that Relypsa will post ($6.33) EPS for the current year.
In other Relypsa news, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of the business’s stock in a transaction on Monday, July 25th. The stock was sold at an average price of $32.00, for a total transaction of $129,395,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder James D. Dondero sold 37,000 shares of the business’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $31.96, for a total value of $1,182,520.00. The disclosure for this sale can be found here.
Institutional investors have recently added to or reduced their stakes in the company. Societe Generale bought a new position in Relypsa during the second quarter worth $133,000. Janney Montgomery Scott LLC acquired a new position in shares of Relypsa during the second quarter valued at approximately $262,000. Legal & General Group Plc raised its position in shares of Relypsa by 15.4% in the first quarter. Legal & General Group Plc now owns 9,448 shares of the company’s stock valued at $127,000 after buying an additional 1,263 shares during the period. BlackRock Group LTD raised its position in shares of Relypsa by 49.8% in the first quarter. BlackRock Group LTD now owns 9,887 shares of the company’s stock valued at $134,000 after buying an additional 3,287 shares during the period. Finally, Laurion Capital Management LP acquired a new position in shares of Relypsa during the second quarter valued at approximately $185,000.
Relypsa Company Profile
Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Relypsa Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc. and related companies with MarketBeat.com's FREE daily email newsletter.